Skip to main content
. 2024 Jun 5;24:130. doi: 10.1186/s12874-024-02256-9

Table 2.

Adherence to ACE checklist

Section topic Total (%)
(n = 108)
JCR Q1(%)
(n = 71)
Others (%)
(n = 37)
P value
Title and abstract 1 Title and abstract 70(64.8) 50(70.4) 20(54.1) 0.14
Introduction 2 Background and objectives 95(88.0) 63(88.7) 32(86.5) 0.98
Methods 3 Trial design 92(85.2) 63(88.7) 29(78.4) 0.25
4 Participants 78(72.2) 49(69.0) 29(78.4) 0.42
5 Interventions 88(81.5) 58(81.7) 30(81.1) 1.00
6 Outcomes 72(66.7) 49(69.0) 23(62.2) 0.62
7 Sample size and operating characteristics 59(54.6) 40(56.3) 19(51.4) 0.77
Randomization 8 Sequence generation 29(26.9) 18(25.4) 11(29.7) 0.80
9 Allocation concealment mechanism 34(31.5) 25(35.2) 9(24.3) 0.35
10 Implementation 24(22.2) 17(23.9) 7(18.9) 0.72
11 Blinding 12(11.1) 8(11.3) 4(10.8) 1.00
12 Statistical methods 59(54.6) 40(56.3) 19(51.4) 0.77
Results 13 Participant flow 37(34.3) 22(31.0) 15(40.5) 0.44
14 Recruitment and adaptations 65(60.2) 37(52.1) 28(75.7) 0.03
15 Baseline data 25(23.1) 10(14.1) 15(40.5) < 0.01
16 Numbers analysed 100(92.6) 66(93.0) 34(91.9) 1.00
17 Outcomes and estimation 23(21.3) 12(16.9) 11(29.7) 0.19
18 Ancillary analyses 94(87.0) 63(88.7) 31(83.8) 0.67
19 Harms 103(95.4) 67(94.4) 36(97.3) 0.84
Discussion 20 Limitations 34(31.5) 20(28.2) 14(37.8) 0.42
21 Generalisability 17(15.7) 11(15.5) 6(16.2) 1.00
22 Interpretation 107(99.1) 70(98.6) 37(100) 1.00a
Other information 23 Registration 65(60.2) 43(60.6) 22(59.5) 1.00
24a Protocol 23(21.3) 18(25.4) 5(13.5) 0.24
24b SAP and other relevant documents 8(7.4) 6(8.5) 2(5.4) 0.85
25 Funding 92(85.2) 61(85.9) 31(83.8) 0.99

Values in parentheses are percentages unless indicated otherwise

aFisher’s exact test